TT-232

Summary

TT-232 is a synthetic cyclic heptapeptide derived from somatostatin. It is being investigated as a research compound for analgesic, anti‑inflammatory and anticancer applications. The peptide shows high affinity for somatostatin receptor subtype 4 (SST4) and also interacts with SST1, providing a non‑endocrine mode of action that distinguishes it from native somatostatin.

Mechanism of Action

TT‑232 binds to the extracellular pocket of the G‑protein‑coupled SST4 receptor with an interaction energy comparable to known agonists, acting as a selective SST4 agonist. Activation of SST4 reduces intracellular cAMP, dampening neurogenic inflammation and nociceptive signalling. In tumour cells, TT‑232 also engages SST1 and a tumour‑specific pyruvate kinase isoform, inhibiting tyrosine‑kinase cascades, inducing cell‑cycle inhibitors and promoting apoptosis, without stimulating hormone release.

What the Research Shows

Pre‑clinical work shows that TT‑232 displaces somatostatin from SST4 (10 nM‑30 µM) and lowers forskolin‑stimulated cAMP (EC50 ≈ 372 nM). In mouse models of chronic neuropathic pain and arthritis, intraperitoneal doses of 100‑200 µg/kg produced 35‑50 % analgesia, an effect absent in SST4‑knockout mice, indicating receptor‑mediated action. Anticancer studies report dose‑dependent inhibition of tumour growth in multiple human cell lines (colon, pancreas, melanoma, etc.) and xenograft models, with 54‑98 % tumour suppression at 30‑750 µg/kg/day and synergistic effects when combined with standard chemotherapeutics. A 2005 report notes successful completion of a phase‑I trial without notable toxicity and ongoing phase‑II studies for oncologic and inflammatory indications. Reviews summarise the analgesic, anti‑inflammatory and antitumor potential, emphasizing the lack of endocrine side effects.

Reported Benefits

Animal data suggest TT‑232 can relieve neuropathic and inflammatory pain through SST4 activation, offering an alternative to opioids with fewer side‑effects. In vitro and xenograft studies demonstrate broad antiproliferative activity across diverse tumour types and enhancement of chemotherapy efficacy, supporting its candidacy as a targeted anticancer agent. The peptide’s selective receptor profile appears to avoid the hormonal disturbances typical of native somatostatin analogues.

Limitations of the Evidence

All efficacy evidence is confined to rodent pain models, cell‑culture assays and mouse xenografts; no peer‑reviewed human efficacy data are available. Phase‑I safety data are limited to the absence of overt toxicity, but detailed adverse‑event profiles, pharmacokinetics and long‑term tolerability remain unreported. The dual receptor activity (SST4 and SST1) raises the possibility of off‑target effects that have not been fully characterised in clinical settings.

Safety Considerations

A phase‑I trial reported no significant toxicity or endocrine disturbances, and pre‑clinical studies did not observe hormone‑related side effects. Nonetheless, the safety profile in humans is incomplete; potential immunogenicity, injection‑site reactions, or unforeseen receptor‑mediated effects cannot be excluded. Caution is warranted until comprehensive clinical safety data are published.

How It Is Administered

TT‑232 is formulated as a peptide for parenteral use. Pre‑clinical investigations employed intraperitoneal injection, while the listed routes of administration include intravenous and subcutaneous delivery. No oral or topical formulations have been described in the literature.

Routes of Administration

Goals & Uses

• Induction of tumor cell apoptosisOncologyModerate
• Solid tumor treatmentOncologyLow
• Neuroendocrine tumor managementOncologyLow
• Antiangiogenic effectOncologyLow

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Known hypersensitivity to somatostatin analoguesAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• HypoglycemiaMetabolicRareAbnormally low blood glucose
• Injection site reactionsLocalCommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• FatigueGeneralUncommonLow energy or tiredness

Drug Interactions

• Chemotherapeutic agentsModerate
• Insulin / Oral hypoglycemicsLow

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with severe renal impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionInvestigationalPhase I/II clinical investigations conducted in Hungary; no EMA marketing authorization.
• United StatesInvestigationalNot FDA-approved; no IND filing publicly confirmed; research compound only.
• United KingdomUnknownNo MHRA approval; status mirrors EU investigational classification.

No approved indications in any major jurisdiction. Investigated in Phase I/II clinical trials in Europe (particularly Hungary). Not FDA-approved. Orphan or special research-use designations may apply in some contexts.

Evidence & Sources

• The heptapeptide somatostatin analogue TT-232 exerts analgesic and anti-inflammatory actions via SST(4) receptor activation: In silico, in vitro and in vivo evidence in mice
  Journal ArticleLowBörzsei R, et al.2023-01-01T00:00:00.000000Z
• TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases
  Journal ArticleModerateSzokolóczi O, et al.2005-01-01T00:00:00.000000Z
• TT-232: a somatostatin structural derivative as a potent antitumor drug candidate
  Journal ArticleModerateSzende B, Kéri G2003-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleModerateBayés M, Rabasseda X, Prous JR2004-01-01T00:00:00.000000Z
• Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity
  Journal ArticleModerateTeplán I2000-01-01T00:00:00.000000Z
• Inhibition of the function of TRPV1-expressing nociceptive sensory neurons by somatostatin 4 receptor agonism: mechanism and therapeutical implications
  Journal ArticleModerateSzolcsányi J, et al.2011-01-01T00:00:00.000000Z

Frequently Asked Questions